MediWound Ltd. (MDWD) stock analysis
Healthcare · Biotechnology
From the 20-F filed 2026-03-05
How it makes money
It earns by selling NexoBrid to hospitals and distributors, supplemented by development fees from government agencies for its research.
Profitability is driven by volume growth of its lead product, NexoBrid, and its ability to secure regulatory approvals in new jurisdictions. The business model combines commercial revenue from wound care products with contract-based funding from organizations like BARDA for medical countermeasure development.
What protects it: the moat
It relies on patented enzymatic technology and complex, sterile manufacturing capabilities to maintain a competitive moat.
The company asserts protection through its patented platform and specialized sterile production facilities, which require cGMP certification. It also highlights industry validation from strategic collaborations with large wound care companies as a defensive layer.
What growth costs
It must heavily reinvest in multi-year clinical trials and manufacturing expansions to realize its pipeline potential.
Growth requires high capital expenditures for clinical studies, which are costly and have uncertain outcomes. The firm also invests in expanding production capacity and upgrading manufacturing facilities to support global demand.
What could damage it
A failure in clinical trials or a regulatory rejection would permanently impair its ability to commercialize pipeline products.
Because the business model depends on the successful regulatory approval and commercialization of pipeline candidates, an inability to secure these approvals at its own expense would destroy the value of the significant research capital already committed.
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.